Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementing an Electronic End-of-Life Chemotherapy Utilization Measure.
Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. Kraut J, et al. Among authors: sweetenham jw. J Oncol Pract. 2019 Apr;15(4):220-223. doi: 10.1200/JOP.18.00408. Epub 2019 Mar 18. J Oncol Pract. 2019. PMID: 30883256 No abstract available.
Prioritizing Measures That Matter Within a Person-Centered Oncology Learning Health System.
Van Citters AD, Kennedy AM, Kirkland KB, Dragnev KH, Leach SD, Buus-Frank ME, Malcolm EF, Holthoff MM, Holmes AB, Nelson EC, Reeves SA, Tosteson ANA; Promise Partnership Delphi Panel. Van Citters AD, et al. JNCI Cancer Spectr. 2022 May 2;6(3):pkac037. doi: 10.1093/jncics/pkac037. JNCI Cancer Spectr. 2022. PMID: 35736219 Free PMC article.
Following aggressive B-cell lymphoma.
Sweetenham JW. Sweetenham JW. Blood. 2015 Jun 11;125(24):3673-4. doi: 10.1182/blood-2015-04-641738. Blood. 2015. PMID: 26069330 Free article.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Moskowitz CH, et al. Among authors: sweetenham j. Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28. Blood. 2018. PMID: 30266774 Free article. Clinical Trial.
Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting.
Nademanee A, Sureda A, Stiff P, Holowiecki J, Abidi M, Hunder N, Pecsok M, Uttarwar M, Purevjal I, Sweetenham J. Nademanee A, et al. Among authors: sweetenham j. Biol Blood Marrow Transplant. 2018 Nov;24(11):2354-2359. doi: 10.1016/j.bbmt.2018.05.026. Epub 2018 May 30. Biol Blood Marrow Transplant. 2018. PMID: 29859255 Free article. Clinical Trial.
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.
Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH. Ramsey SD, et al. Among authors: sweetenham jw. Br J Haematol. 2016 Dec;175(5):860-867. doi: 10.1111/bjh.14316. Epub 2016 Sep 21. Br J Haematol. 2016. PMID: 27649689 Free PMC article. Clinical Trial.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Moskowitz CH, et al. Among authors: sweetenham j. Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19. Lancet. 2015. PMID: 25796459 Clinical Trial.
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, Yang J, Busman TB, Enschede SH, Humerickhouse RA, Seymour JF. Roberts AW, et al. Among authors: sweetenham jw. Br J Haematol. 2015 Sep;170(5):669-78. doi: 10.1111/bjh.13487. Epub 2015 May 5. Br J Haematol. 2015. PMID: 25942994 Free PMC article. Clinical Trial.
152 results